The 21 bp long Patisiran is one of the few approved therapeutic siRNA molecules and is used to treat hereditary transthyretin amyloidosis by knocking down transthyretin mRNA (both mutant form and wild type) produced in the liver [132]. Here, TTR is linked to amyloidosis.